We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Humana (HUM) Gains As Market Dips: What You Should Know
Read MoreHide Full Article
Humana (HUM - Free Report) closed at $488.97 in the latest trading session, marking a +0.67% move from the prior day. This move outpaced the S&P 500's daily loss of 0.93%. Elsewhere, the Dow lost 0.43%, while the tech-heavy Nasdaq lost 0.17%.
Coming into today, shares of the health insurer had gained 6.83% in the past month. In that same time, the Medical sector gained 6.13%, while the S&P 500 gained 6.31%.
Investors will be hoping for strength from Humana as it approaches its next earnings release, which is expected to be July 27, 2022. On that day, Humana is projected to report earnings of $7.67 per share, which would represent year-over-year growth of 11.32%. Meanwhile, our latest consensus estimate is calling for revenue of $23.38 billion, up 13.24% from the prior-year quarter.
For the full year, our Zacks Consensus Estimates are projecting earnings of $24.65 per share and revenue of $93.09 billion, which would represent changes of +19.43% and +12.08%, respectively, from the prior year.
Investors might also notice recent changes to analyst estimates for Humana. Recent revisions tend to reflect the latest near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. The Zacks Consensus EPS estimate remained stagnant within the past month. Humana is holding a Zacks Rank of #3 (Hold) right now.
Looking at its valuation, Humana is holding a Forward P/E ratio of 19.71. Its industry sports an average Forward P/E of 17.6, so we one might conclude that Humana is trading at a premium comparatively.
Meanwhile, HUM's PEG ratio is currently 1.4. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. HUM's industry had an average PEG ratio of 1.17 as of yesterday's close.
The Medical - HMOs industry is part of the Medical sector. This group has a Zacks Industry Rank of 44, putting it in the top 18% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Humana (HUM) Gains As Market Dips: What You Should Know
Humana (HUM - Free Report) closed at $488.97 in the latest trading session, marking a +0.67% move from the prior day. This move outpaced the S&P 500's daily loss of 0.93%. Elsewhere, the Dow lost 0.43%, while the tech-heavy Nasdaq lost 0.17%.
Coming into today, shares of the health insurer had gained 6.83% in the past month. In that same time, the Medical sector gained 6.13%, while the S&P 500 gained 6.31%.
Investors will be hoping for strength from Humana as it approaches its next earnings release, which is expected to be July 27, 2022. On that day, Humana is projected to report earnings of $7.67 per share, which would represent year-over-year growth of 11.32%. Meanwhile, our latest consensus estimate is calling for revenue of $23.38 billion, up 13.24% from the prior-year quarter.
For the full year, our Zacks Consensus Estimates are projecting earnings of $24.65 per share and revenue of $93.09 billion, which would represent changes of +19.43% and +12.08%, respectively, from the prior year.
Investors might also notice recent changes to analyst estimates for Humana. Recent revisions tend to reflect the latest near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. The Zacks Consensus EPS estimate remained stagnant within the past month. Humana is holding a Zacks Rank of #3 (Hold) right now.
Looking at its valuation, Humana is holding a Forward P/E ratio of 19.71. Its industry sports an average Forward P/E of 17.6, so we one might conclude that Humana is trading at a premium comparatively.
Meanwhile, HUM's PEG ratio is currently 1.4. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. HUM's industry had an average PEG ratio of 1.17 as of yesterday's close.
The Medical - HMOs industry is part of the Medical sector. This group has a Zacks Industry Rank of 44, putting it in the top 18% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.